about
Vaccination with Killed but Metabolically Active E. coli Over-expressing Hemagglutinin Elicits Neutralizing Antibodies to H1N1 Swine Origin Influenza A VirusMucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challengeClinical protection against caprine herpesvirus 1 genital infection by intranasal administration of a live attenuated glycoprotein E negative bovine herpesvirus 1 vaccine.Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccineFormulation and characterization of nanoemulsion intranasal adjuvants: effects of surfactant composition on mucoadhesion and immunogenicity.PLGA, PLGA-TMC and TMC-TPP nanoparticles differentially modulate the outcome of nasal vaccination by inducing tolerance or enhancing humoral immunity.Fc receptor-targeting of immunogen as a strategy for enhanced antigen loading, vaccination, and protection using intranasally administered antigen-pulsed dendritic cellsProbing local innate immune responses after mucosal immunisationRobust IgA and IgG-producing antibody forming cells in the diffuse-NALT and lungs of Sendai virus-vaccinated cotton rats associate with rapid protection against human parainfluenza virus-type 1Preparation and efficacy of a live newcastle disease virus vaccine encapsulated in chitosan nanoparticles.Mucosal adjuvant properties of the Shigella invasin complexEndocineā¢, N3OA and N3OASq; three mucosal adjuvants that enhance the immune response to nasal influenza vaccination.Vaginal immunization to elicit primary T-cell activation and dissemination.Clonally related CD8+ T cells responsible for rapid population of both diffuse nasal-associated lymphoid tissue and lung after respiratory virus infectionIntranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine.Intranasal administration of an inactivated Yersinia pestis vaccine with interleukin-12 generates protective immunity against pneumonic plagueMicroneedle Vaccination Elicits Superior Protection and Antibody Response over Intranasal Vaccination against Swine-Origin Influenza A (H1N1) in MiceImmunological aspects of polymer microsphere vaccine delivery systems.Nasal immunization with Burkholderia multivorans outer membrane proteins and the mucosal adjuvant adamantylamide dipeptide confers efficient protection against experimental lung infections with B. multivorans and B. cenocepaciaReduced frequencies and heightened CD103 expression among virus-induced CD8(+) T cells in the respiratory tract airways of vitamin A-deficient miceAdherence-inhibitory intestinal immunoglobulin a antibody response in baboons elicited by use of a synthetic intranasal lectin-based amebiasis subunit vaccine.Passive immunoprotection targeting a secreted CAMP factor of Propionibacterium acnes as a novel immunotherapeutic for acne vulgarisImprove protective efficacy of a TB DNA-HSP65 vaccine by BCG priming.Preventive Activity against Influenza (H1N1) Virus by Intranasally Delivered RNA-Hydrolyzing Antibody in Respiratory Epithelial Cells of Mice.Vitamin A deficiency disrupts vaccine-induced antibody-forming cells and the balance of IgA/IgG isotypes in the upper and lower respiratory tractIntranasal immunization with recombinant Toxoplasma gondii actin depolymerizing factor confers protective efficacy against toxoplasmosis in mice.Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis.Noninvasive delivery technologies: respiratory delivery of vaccines.Roles of Mucosal Immunity against Mycobacterium tuberculosis InfectionNK cells influence both innate and adaptive immune responses after mucosal immunization with antigen and mucosal adjuvant.Chitosan-Based Intranasal Vaccine against Escherichia coli O157:H7.Strategies for intranasal delivery of vaccinesIntranasal vaccination of infant mice induces protective immunity in the absence of nasal-associated lymphoid tissue.Differential localization and function of antibody-forming cells responsive to inactivated or live-attenuated influenza virus vaccinesImplication of nanoparticles/microparticles in mucosal vaccine delivery.Nasal vaccination stimulates CD8(+) T cells for potent protection against mucosal Brucella melitensis challengeEffect of Experimental Parameters on Alginate/Chitosan Microparticles for BCG Encapsulation.Nicotine vaccines to assist with smoking cessation: current status of research.Mouse models for the study of mucosal vaccination against otitis media.Treg inducing adjuvants for therapeutic vaccination against chronic inflammatory diseases
P2860
Q30401849-B551B389-CEAA-4AFC-878D-4E9A13D65810Q33284583-A508152B-2E4D-4400-A011-FBC1FC46881AQ33308325-E722FBA0-92E1-4F41-9F3A-1753E29CD243Q33359620-D89D3A14-BCDB-4E30-B104-756D14F4BC28Q33650861-8A66B8CC-4598-42AE-9632-78237162C115Q34071603-BEF53269-8561-4B6B-849A-F16898225C05Q34087802-062ECAFC-82EF-4541-9E00-A990BFADBF14Q34154378-7507A3FA-A13F-4B4A-800D-9831739C48B8Q34175747-2935AE8B-6A48-4B27-9C37-12AE88C6E31BQ34535130-67B23FD2-185C-43CD-AA2B-BBF2ED399C5BQ34601845-3119CA0F-7B5D-4A2B-B99D-E068BB0E2984Q34947144-F4AD70B3-CE49-445C-A189-D7E9225F2F33Q35069383-77A690A8-8B9B-4CC6-BF13-62E6C88AEB73Q35091189-9EA2892F-C2AC-4383-B53A-20E8A9EEAF84Q35112676-E1BEA360-A667-4FEF-BD1A-01269740421EQ35530270-21824BBC-7A8F-404D-B657-28A080A1C3E7Q35667123-73CB92D1-5749-48E2-929D-1A5DDDC25F39Q35809248-0EDC665A-ADB7-49DF-884C-44F169276405Q35913531-E2361545-68A6-4A8F-B3E6-347C83DA405EQ35940739-32ACA75C-9278-4F1A-A3B6-57F8FA5332BDQ35949888-E023B066-5A92-4231-87BE-934A369BF77EQ36072897-844224CC-3BC4-4531-9901-2E4B93FE1246Q36094423-7D04EC9C-68B1-45D0-A209-B821BA14C1C9Q36096447-77259A5A-DB87-4A2B-9B3B-0C006364F0C1Q36144543-6EBFF76B-C317-4256-BD04-0570255E5715Q36156444-0A7B6F3D-041F-454F-BFB5-5F80F8433570Q36229158-9D5AE613-F0F5-45E1-93DE-6AA34E345FEAQ36349694-3BB05699-6887-4F89-BF1D-E4CF60F8CA3BQ36417953-EB713ABF-3DCC-4FB9-B77A-4E2D9368BB2FQ36455293-00E777F7-197A-498A-8CB3-82155ABD1B7AQ36502198-34E3B42C-2037-470A-9614-5A542794B01AQ36514771-071DECB2-7CF4-4962-B616-CD3DA42FD264Q36571911-3D06B882-18E6-45CB-9E30-CFB4F697D4DDQ36629013-77529B06-4569-495E-9C4E-EA36EFB41B39Q36837152-893A0D22-0F23-4EBF-B38F-AAC45D3C6AC8Q36932453-0CD6AE56-588D-4770-8449-3A9C2FB49335Q36941463-23A154F7-1540-4785-8387-BD6C0A0CCC56Q36987118-A734EB01-74AE-4F63-9E0A-6FFC9AE87C34Q37093093-8309FE29-AFBB-4907-A388-9CC4BB93BAD8Q37105550-A01373B9-676E-4FD0-A3AA-B5A2C187DEE8
P2860
description
2001 nĆ® lÅ«n-bĆ»n
@nan
2001 Õ©ÕøÖÕ”ÕÆÕ”Õ¶Õ« ÕÕ„ÕŗÕæÕ„Õ“Õ¢Õ„ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕøÖÕ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ ÕµÖ
Õ¤ÕøÖÕ”Õ®
@hyw
2001 Õ©Õ¾Õ”ÕÆÕ”Õ¶Õ« Õ½Õ„ÕŗÕæÕ„Õ“Õ¢Õ„ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕ¾Õ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ Õ°ÕøÕ¤Õ¾Õ”Õ®
@hy
2001幓ć®č«ę
@ja
2001幓č«ę
@yue
2001幓č«ę
@zh-hant
2001幓č«ę
@zh-hk
2001幓č«ę
@zh-mo
2001幓č«ę
@zh-tw
2001幓č®ŗę
@wuu
name
Nasal vaccines.
@ast
Nasal vaccines.
@en
Nasal vaccines.
@nl
type
label
Nasal vaccines.
@ast
Nasal vaccines.
@en
Nasal vaccines.
@nl
prefLabel
Nasal vaccines.
@ast
Nasal vaccines.
@en
Nasal vaccines.
@nl
P1476
Nasal vaccines.
@en
P2093
P356
10.1016/S0169-409X(01)00162-4
P407
P577
2001-09-01T00:00:00Z